Using next-generation sequencing to detect infections in neutropenic patients with fever

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of the DISQVER platform, which utilizes next-generation sequencing (NGS), for diagnosing bloodstream infections in patients experiencing febrile neutropenia. It is a multi-centre study that will gather data from various hospitals to assess the diagnostic capabilities of this innovative approach. By focusing on neutropenic patients with fever or sepsis, the study seeks to provide valuable insights into the timely identification of infections in this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Informed consent
* Neutropenia defined as \<500 ANC (Absolute neutrophil Count)/µl or \<1000 WBC (White bloddcell Count)/µl if ANC is not available
* Fever (with an onset \< 24h) or Sepsis (with an onset \<24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.

Exclusion Criteria:

* Age \< 18 years
* Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
* Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
* Death is deemed imminent and inevitable

Where it's running

• University Hospital of Cologne
  Cologne, Germany Recruiting
• Hospital Dessau
  Dessau, Germany Recruiting
• University Hospital of Essen
  Essen, Germany Recruiting
• University Hospital of Frankfurt
  Frankfurt am Main, Germany Recruiting
• University Hospital of Leipzig
  Leipzig, Germany Recruiting
• University Hospital of Magdeburg
  Magdeburg, Germany Recruiting

Study contacts

• Study coordinator: Boris Böll
• Email: boris.boell@uk-koeln.de
• Phone: +4922147842579

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma Host-Microbe Proteomics to Predict Complications in High-Risk Febrile Neutropenia

  Researchers will test a combined host and microbial blood proteome to see if it can predict which high-risk febrile neutropenia patients will develop complications.

  Recruiting Instituto de Investigación Biomédica de Salamanca · Barcelona, Barcelona and 2 other locations · NCT07277387

• Stepwise antibiotic and antifungal treatment for febrile neutropenia in blood cancer patients

  This treatment plan tests whether a stepwise escalation of antibiotics and antifungals can control infection and fever in adults with hematologic malignancies who develop febrile neutropenia.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07204522

• Comparing Ceftolozane/Tazobactam and Meropenem for Febrile Neutropenia in Patients at Risk for ESBL Infections

  This study is testing if a new antibiotic called Ceftolozane/Tazobactam works just as well as Meropenem for people with febrile neutropenia who are at risk for certain infections.

  Recruiting Phase 4 Beneficência Portuguesa de São Paulo · São Paulo · NCT06342115

• Adjusting antibiotic doses for children with cancer and infections

  This study is testing how to adjust antibiotic doses for children with cancer who have infections to make sure they get the right amount of medicine when their kidneys clear it from their bodies too quickly.

  Recruiting Phase 4 Centre Hospitalier Universitaire Vaudois · Lausanne, Canton of Vaud · NCT06293677

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.